This web page was produced as an assignment for an undergraduate course at Davidson College.

 

References

Schizophrenia

Azorin, Jean-Michel, et al. A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Sever Chronic Schizophrenia. American Journal of Psychiatry 158 (2001): 1305-1313.

Carpenter, William, et al. A Comparative Trial of Pharmacologic Strategies in Schizophrenia American Journal of Psychiatry 144 (1987): 1466-1470.

Conley, Robert and Mahmoud, Ramy. A Randomized Double-Blind study of Risperidone and Olanzapine in the Treatment of Shizophrenia or Schizoaffective Disorder  American Journal of Psychiatry 158 (2001): 765-774.

Cooper, SJ, et al. Zotepine in the Prevention of Recurrence: A Randomised, Double-Blind, Placebo-Controlled Study for Chronic Schizophrenia Psychopharmacology 150 (2000) 237-243.

Kane, Jonathon and De Scipio, William. Acupuncture Treatment of Schizophrenia: Report on Three Cases American Journal of Psychiatry 136 (1979): 297-302.

Kane, J, et al. Clozaril Collaborative Group: Clozapine for Treatment-Resistant Schizophrenia: A double-blind Comparison with Chlorpromazine Archives of General Psychiatry 45 (1988): 789-796.

May, Philip, Tuma, Hussain, and Dixon, Wilfrid. For Better or For Worse? The Journal of Nervous and Mental Disease 165 (1977): 231-239.  

Schreiber, Stephen et al. Dialysis for Schizophrenia: An Uncontrolled Study of 11 Patients. American Journal of Psychiatry 138 (1981): 662-665.

Srmaek, John, et al. A Carbamazepine Trial in Chronic, Treatment-Refractory Schizophrenia American Journal of Psychiatry 145 (1988): 145-146.

Wagemaker, H Jr, and Cade R.  The use of Hemodialysis in Chronic Schizophrenia American Journal of Psychiatry 134 (1977): 684-685

Young, Carl, et al. The Expanding Indications for Clozapine Experimental and Clinical Psychopharmacology 5.3 (1997): 216-234.

 

Alcoholism

Bruno, F. Buspirone in the Treatment of Alcoholic Patients. Psychopathology Suppl. 1 (1989): 46-59.

Davidson D et al The Effects of Naltrexone on Alcohol Self-Administration in Heavy Drinkers.  Alcohol: Clinical and Experimental Research 23(1999): 195-203.

Dorus, 1989, et al. Lithium Treatment of Depressed and Nondepressed Alcoholics JAMA 262 (1989): 1646-1652.

Doty P, Zacny J, and deWit H. The Effects of Ondansetron Pretreatment on Acute Responses to Ethanol in Social Drinkers. Behavioral Pharmacology 5(1994): 461-469.  

Fawcett, Jan et al. Pharmacological Treatments for Alcoholism: Revisiting LIthium and Considering Buspirone Alcoholism: Clinicla and Experimental Research 24 (2000): 666-673

Humphreys, Keith and Moos, Rudolf. Can Encouraging Substance Abuse Patients to Participate in Self-Help Groups Reduce Demand for Health Care?  A Quasi-Experiemental Study. Alcoholism: Clinical and Experimental Research 25 (2001): 711-716.

Johnson, Bankole and Ait-Daoud, Nassima. Neuropharmacological Treatments for Alcoholism: Scientific Basis and Clinical Findings Psychopharmacology 149 (2000): 327-344.

Johnson, et al Attenuation of some Alcohol-Induced Mood Changes and the Desire to Drink by 5-HT3 Receptor Blockade: A Preliminary Study in Healthy Male Volunteers.  Psychopharmacology 112(1993): 142-144

Litten RZ, Allen J, and Fertig J. Advances in the Development of Medications for Alcoholism.  Psychopharmacology 139 (1998): 20-33  

Monti, Peter et al. Naltrexone and Cue  Exposure with Coping and Communication Skills Training for Alcoholics: Treatment Process and 1-Year Outcomes Alcoholism: Clinical and Experiemental Research 25 (2001): 1634-1647.

Myers RD and Veale, WL Alcohol preference in the rat: Reduction following Depletion of Brain Serotnoin. Science 160 (1968): 1469-1471  

Nielsen, Bent, Neilse, Anette, and Wraae, Olaf. Patient-Treatment Matching Improves Complaince of Alcoholics in Outpatient Treatment The Journal of Nervous and Mental Disease 186 (1998): 752-760.

O’Malley SS, et al Naltrexone and coping skills therapy for Alcohol Dependence: A Controlled Study Archives of General Psychiatry 49 (1992): 881-887

Poldrugo F Acamprosate Treatment in a Long-Term Community-based Alcohol Rehabilitation Program. Addiction 92 (1997): 1537-1546

Sellers, et al Clinical Efficacay of the 5-HT3 Antagonist Ondansetron in Alcohol Abuse and Dependence Alcohol: Clinical and Experimental Research 18(1994):879-885.

Swift, et al Oncansetron alters Human Alcohol Inotoxication Biological Psychiatry 40(1996): 514-521

Volpicelli JR et al Nalterxone in the treatment of Alcohol Dependence Archives of General Psychiatry 49 (1992): 876-880

Volpicelli JR et al. Nalterxone and Alcohol Dependence.  Role of Subject Compliance Archives of General Psychiatry 54 (1997): 737-74

 

Other Substances

Bisaga, A., Gianelli, P., Popik, P. Opiate Withdrawal with Dextromethorphan American Journal of Psychiatry.  154 (1997):584

Bisaga, Adam and Popik, Piotr.  In search of a New Pharmacological Treatment for Drug and Alcohol Addiction: N-methyl-D-aspartate (NMDA) antagonists Drug and Alcohol Dependence 59 (2000): 1-15

Carroll, Kathleen Relapse Prevention as a Psychosocial Treatment: A Review of Controlled Clinical Trials Environmental and Clinical Psychopharmacology 4 (1996): 46-54.  

Humphreys, Keith et al Do Enhanced Friendship Networks and Active Coping Mediate the Effect of Self-Help Groups on Substance Abuse The Society of Behavioral Medicine 21 (1999): 54-60.

Killen, JD, Maccoby N, and Taylor, CB Nicotine Gum and Self-Regulation Training in Smoking Relapse Prevention Behavior Therapy 15 (1984): 234-248.  

Rosen, et al. A Pilot Study of Dextromethorphan in Nalonxone-Precipitated Opiate Withdrawal.  European Journal of Pharmacology 307 (1996): 251-257

Turner, Samuel. Comments on Expressed Emotion and the Development of New Treatments for Substance Abuse Behavior Therapy 29 (1998):647-654

 

Improved Technology

May, Philip, Tuma, Hussain, and Dixon, Wilfrid. For Better or For Worse? The Journal of Nervous and Mental Disease 165 (1977): 231-239.  

Staddon, Susan, et al. Clinical Applications of Pharmacogenetics in Psychiatry.  Psychopharmacology 162 (2002): 18-23

 

                                                                                                                                                                                                                      

Return to the Schizophrenia, Alcoholism, Other Substances, or Improved Technology Section

Return to Megan's Behavioral Genomics Homepage

Return to Megan's Genomics Homepage        

Davidson College Psychology Department  

                                                                                                                                                                                                                           

© Copyright 2002 Department of Psychology, Davidson College, Davidson, NC 28036
Send comments, questions, and suggestions to: meshafer@davidson.edu